FDA’s latest move to integrate patient input into regulatory decision-making on drugs, devices and biologics is a May 18 meeting to be held at the agency’s White Oak, Silver Spring, Md. headquarters.
The agency says it will welcome patients, caregivers, independent patient advocates, patient advocate groups, academics, industry representatives and health professional groups to the meeting